CAM
AARD

Cresset Asset Management’s Aardvark Therapeutics AARD Stock Holding History

Cresset Asset Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Buy
+43,259
New +$448K ﹤0.01% 1503
2025
Q4 		– Sell
-141,783
Closed -$1.88M – 1713
2025
Q3 		$1.88M Buy
+141,783
New +$1.6M 0.01% 553

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cresset Asset Management's AARD Position: Q1 2026 in Review

Cresset Asset Management opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 43,259 shares worth $163K. The stake represents ﹤0.01% of the portfolio and ranks #1503 among its holdings. This is a return to the name: Cresset Asset Management previously reported a position in AARD as recently as Q3 2025.

Cresset Asset Management first reported a position in AARD in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.88M in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Cresset Asset Management held 43,259 shares of Aardvark Therapeutics worth $163K as of Q1 2026.
  • Aardvark Therapeutics was a new Cresset Asset Management position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1503 holding.
  • Cresset Asset Management first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Cresset Asset Management's Aardvark Therapeutics position peaked at $1.88M in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.